Your browser doesn't support javascript.
loading
Prevalence of Hospital-Onset Bacteremia Pre- and Post-Implementation of a Needleless Blood Sampling Device From Existing Peripheral Catheters.
Yu, Kalvin C; Ai, ChinEn; Jung, Molly; Johnson, Heather; Smith, Scott; LaJoie, Judith; Denny, Gerald.
Affiliation
  • Yu KC; Becton, Dickinson and Company, Franklin Lakes, New Jersey.
  • Ai C; Kalvin Yu, MD, FIDSA, is the vice president of medical and scientific affairs at Becton, Dickinson and Company (BD). Before BD, he was the chief integration officer and chief of infectious diseases at Southern California Kaiser Permanente. He has published on flu vaccine safety, readmissions, qualit
  • Jung M; ChinEn Ai, MPH; Molly Jung, PhD, MPH; and Scott Smith, PhD, are experienced population health researchers with expertise in epidemiology and statistics.
  • Johnson H; Heather Johnson, CIC, is an infection prevention subject matter expert at BD.
  • Smith S; Judith LaJoie, DPN, RN, is the BD senior director of medical affairs for the Medication Delivery Solutions team based in the United States. As a registered nurse for 32 years, Dr LaJoie has worked in several health care spaces, including inpatient care, outpatient services, and now the medical devic
  • LaJoie J; Gerald Denny, MD, is a nephrologist by training and is the BD global medical director for medical affairs for the Medication Delivery Solutions team.
  • Denny G; Becton, Dickinson and Company, Franklin Lakes, New Jersey.
J Infus Nurs ; 46(6): 332-337, 2023.
Article in En | MEDLINE | ID: mdl-37490579
ABSTRACT
Repeated access of peripheral intravenous (IV) devices theoretically increases the risk of bacterial exposure. PIVO™ (VelanoVascular) is a needleless, single-use device that enables blood sampling from an existing peripheral IV. The goal of this retrospective observational exploratory study was to evaluate the influence of PIVO use on rates of hospital-onset bacteremia and fungemia (HOB) by comparing HOB rates in the year before and after PIVO introduction in hospitals implementing PIVO and over similar time periods in "control" hospitals with no PIVO. Two hospitals implementing PIVO (Hospital 1, a large community hospital; Hospital 2, a tertiary oncology center), and 71 control hospitals were included. During the 1-year period before and after PIVO introduction, HOB rates decreased in hospitals 1 and 2 by 31.9% and 41.8%, respectively. Control hospitals that did not use PIVO had a 12.4% decrease in HOB rates. Multivariable logistic regression analyses found that PIVO was associated with a lower risk (Hospital 1 odds ratio [OR] 0.63; 95% CI, 0.42-0.94) or no change (Hospital 2 OR 1.05; 95% CI, 0.72-1.52) in HOB rates. Control hospitals also showed no change in HOB rates between the 2 time periods. These data do not support concerns about increased risk of bacteremia with PIVO.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bacteremia Type of study: Prevalence_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Infus Nurs Journal subject: ENFERMAGEM Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bacteremia Type of study: Prevalence_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Infus Nurs Journal subject: ENFERMAGEM Year: 2023 Document type: Article
...